Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?
12:38pm, Thursday, 08'th Jun 2023
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
12:47pm, Wednesday, 17'th May 2023
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
These 4 Stocks Sport Impressive Interest Coverage Ratio
12:11pm, Thursday, 11'th May 2023
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Stride (LRN), ServiceNow (NOW), Halozyme Therapeutics (HALO) and AM
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
01:41pm, Wednesday, 10'th May 2023
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
07:07pm, Tuesday, 09'th May 2023
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.47 per share a year ago.
Halozyme to Present at Upcoming Investor Conferences
08:30am, Wednesday, 03'rd May 2023
SAN DIEGO , May 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present an
Halozyme's ENHANZE Technology Is The Future Of Biologics Delivery
07:38am, Wednesday, 12'th Apr 2023
Halozyme Therapeutics (HALO) is a biotech company with a unique platform technology, ENHANZE, that allows for the subcutaneous delivery of biologics. Recent CMS guidance related to Medicare drug price
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
04:37am, Tuesday, 21'st Mar 2023
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
10:50am, Friday, 17'th Mar 2023
Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
12:05pm, Thursday, 16'th Mar 2023
Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme ap
Halozyme Therapeutics: A Trailblazer, But With Lukewarm Financials
07:56am, Sunday, 26'th Feb 2023
HALO has mediocre financials, questionable outlook. Absolute market share ensures demand for its products.
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
10:33am, Wednesday, 22'nd Feb 2023
Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.
Halozyme Therapeutics, Inc. (HALO) Q4 2022 Earnings Call Transcript
08:56pm, Tuesday, 21'st Feb 2023
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications
Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates
06:49pm, Tuesday, 21'st Feb 2023
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 2.13% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Halo Therapeutics stock drops following weak 2023 outlook
05:36pm, Tuesday, 10'th Jan 2023
Halozyme Therapeutics Inc. HALO, +1.20% stock fell in the extended session Tuesday after the biotech drug maker's 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hours
